In summary, administration of the SIRT1 activator, SRT3025, to mice with STZ-induced diabetes led to improved glycaemia with reductions in plasma glucagon and α cell hyperplasia without affecting either insulin secretion or ß-cell mass. Here, INS is linked to diabetes mellitus.